NASDAQ:XLRN Acceleron Pharma (XLRN) Stock Price, News & Analysis → Here’s how to start a “Weekend Side Hustle” from your sofa (From DTI) (Ad) Free XLRN Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$178.75▼$178.7550-Day Range$172.08▼$179.6852-Week Range$108.82▼$189.99VolumeN/AAverage Volume572,759 shsMarket Capitalization$10.93 billionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Acceleron Pharma alerts: Email Address Ad DTIHere’s how to start a “Weekend Side Hustle” from your sofaHere’s how you can start your very own “Weekend Side Hustle” right from the comfort of your sofa! It doesn't matter if you have a multi-million dollar retirement account… Or if you’re just starting out with a few thousand.Weekend after weekend! About Acceleron Pharma Stock (NASDAQ:XLRN)Acceleron Pharma, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its product candidates include Luspatercept, designed to patients with chronic anemia associated within a wide range of blood diseases; ACE-083, designed for the treatment of focal muscle disorders; and Sotatercept, designed to treat pulmonary arterial hypertension. The company was founded by John L. Knopf and Thomas P. Maniatis in June 2003 and is headquartered in Cambridge, MA.Read More Ad Wall Street StarThis Apple-like Innovator is Revolutionizing HealthcareAI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.Click here to learn more about the booming eHealth industry XLRN Stock News HeadlinesFebruary 27, 2024 | benzinga.comORBIMED CAPITAL GP II LLC's Net WorthOctober 20, 2023 | investing.comXLRN Historical DataApril 23, 2024 | Whats On Finance (Ad)Putin and other countries have a planDid you catch that bombshell Tucker Carlson interview with Vladimir Putin? It’s not about if you like Tucker or think Putin is the devil or whatever. It's all about the fact that the US dollar might be taking a back seat... and soon. April 15, 2023 | thestreet.comBrexit Bargain Buys: 14 More Stocks Picked by Morgan StanleyMarch 17, 2023 | reuters.comAstellas Pharma IncDecember 14, 2022 | finance.yahoo.comAcceleron Corp Becomes a Digital Correspondent BankNovember 30, 2022 | finance.yahoo.comPharma Contract Sales Market Report 2022-2032November 21, 2022 | reuters.comMerck to buy Imago for $1.35 bln to broaden portfolio of blood disorder drugsApril 23, 2024 | Whats On Finance (Ad)Putin and other countries have a planDid you catch that bombshell Tucker Carlson interview with Vladimir Putin? It’s not about if you like Tucker or think Putin is the devil or whatever. It's all about the fact that the US dollar might be taking a back seat... and soon. October 10, 2022 | msn.comCentre Piece Of Merck's $11.5B Acceleron Buyout Aces Late-Stage Cardiovascular TrialMay 23, 2022 | seekingalpha.comLiquidia slumps as United, MannKind get FDA nod for rival therapyJanuary 20, 2022 | thestreet.com19 Charts to Calm Your Recession FearsDecember 22, 2021 | finance.yahoo.comXLRN May 2022 140.000 putNovember 22, 2021 | finance.yahoo.comMerck Closes Biggest Biotech Deal of the YearNovember 22, 2021 | seekingalpha.comMerck announces completion of Acceleron Pharma acquisitionNovember 21, 2021 | nasdaq.comMerck's (NYSE:MRK) Balance Sheet Can Easily Handle Acquisitions like Acceleron Pharma (NASDAQ: XLRN)November 17, 2021 | apnews.comAvoro Capital Urges Acceleron Shareholders Not to Tender Into Merck’s Inadequate OfferNovember 17, 2021 | nasdaq.comNotable Wednesday Option Activity: XLRN, LOW, ZGNXNovember 17, 2021 | finance.yahoo.comMerck Announces Expiration of Hart-Scott-Rodino Act Waiting Period and Extension of Tender Offer to Acquire Acceleron Pharma Inc.November 17, 2021 | seekingalpha.comMerck says HSR waiting period for Acceleron Pharma deal expiresNovember 15, 2021 | gurufocus.comAvoro Capital Advisors LLC Buys Acceleron Pharma Inc, Apellis Pharmaceuticals Inc, Aadi ...November 15, 2021 | gurufocus.comWestern Standard LLC Buys IHS Markit, Acceleron Pharma Inc, Marlin Business Services Corp, ...November 12, 2021 | finance.yahoo.comSome Acceleron Investors Want a Better Deal From MerckNovember 12, 2021 | msn.comIs Merck's Planned Acquisition of Acceleron in Trouble?November 9, 2021 | finance.yahoo.comAvoro Capital Releases Presentation Detailing Why Acceleron Shareholders Should Not Tender Into Merck’s Inadequate OfferNovember 4, 2021 | chron.comAcceleron: Q3 Earnings SnapshotNovember 4, 2021 | finance.yahoo.comAcceleron Reports Third Quarter 2021 Financial ResultsSee More Headlines Receive XLRN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Acceleron Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/04/2021Today4/23/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological Products, Except Diagnostic Sub-IndustryN/A Current SymbolNASDAQ:XLRN CUSIPN/A CIK1280600 Webwww.acceleronpharma.com Phone(617) 649-9200Fax617-649-9988Employees312Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($4.21) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-166,030,000.00 Net Margins-226.01% Pretax Margin-225.99% Return on Equity-32.11% Return on Assets-29.45% Debt Debt-to-Equity RatioN/A Current Ratio12.14 Quick Ratio12.14 Sales & Book Value Annual Sales$92.52 million Price / Sales118.15 Cash FlowN/A Price / Cash FlowN/A Book Value$11.74 per share Price / Book15.23Miscellaneous Outstanding Shares61,156,000Free Float60,116,000Market Cap$10.93 billion OptionableOptionable Beta0.13 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesHabib J. DablePresident, Chief Executive Officer & DirectorLisa WymanVice President-OperationsKevin F. McLaughlinChief Financial Officer, Treasurer & Senior VPRavindra KumarChief Scientific Officer & Senior Vice PresidentJay T. BackstromExecutive VP & Head-Research & DevelopmentKey CompetitorsBio-TechneNASDAQ:TECHRepligenNASDAQ:RGENQiagenNYSE:QGENNeurocrine BiosciencesNASDAQ:NBIXExelixisNASDAQ:EXELView All Competitors XLRN Stock Analysis - Frequently Asked Questions How were Acceleron Pharma's earnings last quarter? Acceleron Pharma Inc. (NASDAQ:XLRN) released its quarterly earnings data on Thursday, November, 4th. The biopharmaceutical company reported ($1.16) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.98) by $0.18. The biopharmaceutical company earned $34.20 million during the quarter, compared to the consensus estimate of $35.39 million. Acceleron Pharma had a negative trailing twelve-month return on equity of 32.11% and a negative net margin of 226.01%. The business's revenue was up 51.6% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.66) EPS. What is Habib Dable's approval rating as Acceleron Pharma's CEO? 11 employees have rated Acceleron Pharma Chief Executive Officer Habib Dable on Glassdoor.com. Habib Dable has an approval rating of 100% among the company's employees. This puts Habib Dable in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Acceleron Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Acceleron Pharma investors own include Bristol-Myers Squibb (BMY), Advanced Micro Devices (AMD), Gilead Sciences (GILD), NVIDIA (NVDA), Incyte (INCY), Intel (INTC), Pfizer (PFE), Corcept Therapeutics (CORT), Cisco Systems (CSCO) and Regeneron Pharmaceuticals (REGN). This page (NASDAQ:XLRN) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill Publishingtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acceleron Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
